Journals / Retina-Vitreus / 2020 / Cilt: 29 - Sayı: 3

Effi cacy of Intravitreal Bevacizumab Monotherapy in the Treatment of Retinopathy of Prematurity

Pages
198–207
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, long term and close follow up examinations are crucial after IVB injection.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the results of intravitreal bevacizumab (IVB) monotherapy applied for retinopathy of prematurity (ROP) during a 6 year period in a tertiary referral for ROP.
📊
Key Findings & Data:Materials and Methods: The fi les of patients treated with IVB for ROP between January 2012 and October 2018 were evaluated retrospectively.
💡
Conclusion & Impact:Thus, long term and close follow up examinations are crucial after IVB injection.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Özet

Purpose: To evaluate the results of intravitreal bevacizumab (IVB) monotherapy applied for retinopathy of prematurity (ROP) during a 6 year period in a tertiary referral for ROP. Materials and Methods: The fi les of patients treated with IVB for ROP between January 2012 and October 2018 were evaluated retrospectively. Gestational age, birth weight, indications and results of IVB monotherapy and complications were recorded. Results: One hundred twenty three eyes of 69 patients were included in the study. Seventy-six eyes (58.5%) of 40 patients had aggressive posterior retinopathy of prematurity (AP-ROP) and 47 eyes (41.3%) of 29 patients had classic Type 1 ROP. One hundred nine eyes (88.7%) of 62 patients were responsive to initial IVB injection but 14 eyes (11.3) of seven patients were non-responsive. Complete resolution was detected in 76 eyes (69.7%) of 44 patients responsive to initial IVB treatment, whereas in 29 eyes (26.6%) of 16 patients, ROP recurred within a mean period of 8.0 ± 3.0 weeks. In four eyes (3.6%) of two patients, peripheral vascularization was not completed. Conclusion: Although a signifi cant number of patients were responsive to IVB injection, recurrence was an important disadvantage. Thus, long term and close follow up examinations are crucial after IVB injection.

🔖

Cite This Article

KARA, C., PETRICLI, I. S., ARMAN, A., OZCAN, Ç., İYİGÜN, F. (2020). Effi cacy of Intravitreal Bevacizumab Monotherapy in the Treatment of Retinopathy of Prematurity. Retina-Vitreus, Cilt: 29 - Sayı: 3, 198–207. https://ajindex.com/articles/304789

References (9)

  1. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84:77-82
  2. Dogra MR, Katoch D, Dogra M. An Update on Retinopathy of Prematurity (ROP). Indian J Pediatr. 2017;84:930-936
  3. Early Treatment For Retinopathy Of Prematurity Cooperative G. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684-1694
  4. Brooks SE, Johnson M, Wallace DK, et al. Treatment outcome in fellow eyes after laser photocoagulation for retinopathy of prematurity. Am J Ophthalmol. 1999;127:56-61
  5. Banach MJ, Berinstein DM. Laser therapy for retinopathy of prematurity. Curr Opin Ophthalmol. 2001;12:164-170
  6. Mueller B, Salchow DJ, Waffenschmidt E, et al. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol. 2017;101:365-370
  7. Mechoulam H, Pierce EA. Retinopathy of prematurity: molecular pathology and therapeutic strategies. Am J Pharmacogenomics. 2003;3:261-277
  8. Romagnoli C. Risk factors and growth factors in ROP. Early Hum Dev. 2009;85:S79-82
  9. Shah PK, Narendran V, Tawansy KA, et al. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol. 2007;55:75-76. 1 0. Mintz-Hittner HA, Kuffel RR, Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28:831-838. 1 1. Law JC, Recchia FM, Morrison DG, et al. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS. 2010;14:6-10. 1 2. Mintz-Hittner HA. Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors. Early Hum Dev. 2012;88:937-941. 1 3. Harder BC, Schlichtenbrede FC, von Baltz S, et al. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol. 2013;155:1119-1124 e1111. 1 4. Spandau U, Tomic Z, Ewald U, et al. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmol. 2013;91:170-175. 1 5. Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al. Effi cacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603-615. 1 6. Bashshur ZF, Haddad ZA, Schaka